A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients with Episodic Migraine
Phase 2
Completed
- Conditions
- Episodic Migraine
- Registration Number
- JPRN-jRCT2080223373
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients are 18 to 65 years of age
- Have a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders- (ICHD-) 3 beta guidelines (1.1 or 1.2) (HCCIHS 2013).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method